PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'School of Public Health, Imperial College London, London, UK. h.ward@imperial.ac.uk.\', \'National Institute for Health Research Imperial Biomedical Research Centre, London, UK. h.ward@imperial.ac.uk.\', \'Imperial College Healthcare NHS Trust, London, UK. h.ward@imperial.ac.uk.\', \'School of Public Health, Imperial College London, London, UK.\', \'MRC Centre for Global Infectious Disease Analysis Imperial College London, London, UK.\', \'Department of Statistics, University of Oxford, Oxford, UK.\', \'National Institute for Health Research Imperial Biomedical Research Centre, London, UK.\', \'Department of Infectious Disease, Imperial College London, London, UK.\', \'Institute of Global Health Innovation, Imperial College London, London, UK.\', \'School of Public Health, Imperial College London, London, UK. p.elliott@imperial.ac.uk.\', \'National Institute for Health Research Imperial Biomedical Research Centre, London, UK. p.elliott@imperial.ac.uk.\', \'MRC Centre for Environment and Health, Imperial College London, London, UK. p.elliott@imperial.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41467-021-21237-w
?:doi
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 33568663
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
?:title
  • SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all